Dopamine transporter

They've been ongoing for a substantial period of time.

And as I said earlier, there's interest both in Ox1, this programme, and indeed in our DAT programme from a partnering point of view.

So that, with the news flow forecast and the enhanced news flow from the recent raise, brings us to the end of the formal part of the presentation in the summary.

So over to Alistair to sum up for us.

We live with data and patents.

That's our entire value as a business, as an industry.

What are the plans for DAT and SFX01? SFX01 comes up every now and again.

DAT, we mentioned, I think, that there is partnering interest there, too, on several fronts.